First of all, the invention is aimed at treating patients suffering from thrombosis.

Scientists have already conducted experiments on laboratory animals. In particular, experts found out that the effect of the new drug is higher than acetylsalicylic acid in the prevention of arterial thrombosis. K-167 is also able to reduce the number of platelets in the inferior vena cava 6 times more than aspirin, which reduces the development of pulmonary embolism.

The new drug is potentially free from such side effects of aspirin as irritation of the gastric mucosa.